3Niklinski J, Niklinska W, Laudanski J, et al. Prognostlc molecular markers in non-small cell lung cancer [ J ]. Lung Cancer, 2001,34[ Suppl 2] :53-58.
4Bunn PA Jr, Soriano A, Johnson G, et al. New therapeutic strategies for lung cancer: biology and molecular biology come of age [J]. Chest,2000,I1714 Suppl I] :163-168.
5Nelson HH, Christlani DC, Mark JK, et al. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women [J]. J Natl Cancer Inst, 1999,91(23) :2032-2038.
6Huncharek M, Muscat J, C, eschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer:a combined analysis of 881 cases [J]. Carcinogenesis, 1999,20(8) : 1507-1510.
7Kubokura H,Tenjin T.Akiyama H, et al. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in sltu hybridization [J]. Ann Thomc Cardiovasc Surg, 2001,7(4) : 197-203.
9Brebender J, Denenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival [J]. Clin Cancer Res,2001,7(7) : 1850-1855.
10Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer [ J]. Clin Cancer Res,2002,7(4) :861-867.
